CSF3 and breast cancer: A phase III, open-label, randomized multicenter study on 1047 women with high-risk, node-negative BC, reported that the addition of a primary prophylactic granulocyte colony-stimulating factor (G-CSF) to postsurgical chemotherapy with docetaxel, doxorubicin, and cyclophosphamide (TAC) significantly reduced the incidence of dysgeusia (3.1 versus 7.9%, p = 0.0335) compared to TAC without G-CSF [86].